Physician profile
David D Ernst
NPI 1306076518
$2,597.54
in general payments reported to CMS, 2019-2025
18 companies · $537 in 2025
The $537 reported for 2025 was more than what 79% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $243 · 2021: $215 · 2022: $525 · 2023: $325 · 2024: $468 · 2025: $537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,330.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $778.63 | 2022-2025 | Infuse, Miebo, Xiidra |
| Johnson & Johnson Vision Care, INC. | $401.91 | 2019-2025 | Acuvue |
| Coopervision INC. | $252.59 | 2020-2025 | Myday Contact Lens, Misight Contact Lens |
| Alcon Vision LLC | $239.19 | 2019-2025 | Precision7, Total30 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $204.09 | 2019-2021 | |
| Oyster Point Pharma, INC. | $154.18 | 2022-2024 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $111.42 | 2020-2023 | |
| Tarsus Pharmaceuticals, INC. | $74.81 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $58.95 | 2025 | Oxervate |
| Shire North American Group INC | $54.91 | 2019 | |
| Sun Pharmaceutical Industries INC. | $44.81 | 2020-2025 | Cequa |
| Astellas Pharma US INC | $44.56 | 2024 | Izervay |
| Abbvie INC. | $38.47 | 2022 | |
| Allergan, INC. | $34.85 | 2021-2022 | |
| Biotissue Holdings INC. | $32.49 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $24.94 | 2020 | |
| Lkc Technologies, INC. | $24.92 | 2024 | |
| Sight Sciences, INC. | $21.82 | 2025 | Tearcare System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ernst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.